Skip to main content
British Heart Journal logoLink to British Heart Journal
. 1970 May;32(3):326–329. doi: 10.1136/hrt.32.3.326

Bretylium tosylate in prevention of cardiac dysrhythmias after myocardial infarction

S H Taylor 1,2, C Saxton 1,2, P S Davies 1,2, J B Stoker 1,2
PMCID: PMC487328  PMID: 4911756

Abstract

The prophylactic value of parenterally administered bretylium tosylate against the onset of dysrhythmias after acute myocardial infarction has been assessed by a controlled trial in 101 male patients. Bretylium significantly reduced the incidence of supraventricular dysrhythmias but was without significant effect on the incidence of ventricular dysrhythmias. The only serious side-effect of the drug was hypotension which occurred in one-third of the patients. It is concluded that prophylactic treatment of patients suffering from uncomplicated myocardial infarction with parenteral bretylium tosylate probably does not confer sufficient clinical benefit to warrant its recommendation for preventative use in this disease.

Full text

PDF
326

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bacaner M. Bretylium tosylate for suppression of induced ventricular fibrillation. Am J Cardiol. 1966 Apr;17(4):528–534. doi: 10.1016/0002-9149(66)90244-x. [DOI] [PubMed] [Google Scholar]
  2. GILMORE J. P., SIEGEL J. H. Mechanism of the myocardial effects of bretylium. Circ Res. 1962 Mar;10:347–353. doi: 10.1161/01.res.10.3.347. [DOI] [PubMed] [Google Scholar]
  3. Leveque P. E. Anti-arrhythmic action of bretylium. Nature. 1965 Jul 10;207(993):203–204. doi: 10.1038/207203a0. [DOI] [PubMed] [Google Scholar]

Articles from British Heart Journal are provided here courtesy of BMJ Publishing Group

RESOURCES